237 related articles for article (PubMed ID: 25865752)
1. [Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets].
Masana L; Plana N
Clin Investig Arterioscler; 2015; 27(3):138-43. PubMed ID: 25865752
[TBL] [Abstract][Full Text] [Related]
2. Update of therapeutic planning tables oriented towards obtaining therapeutic objectives.
Masana L; Plana N
Clin Investig Arterioscler; 2019; 31(6):271-277. PubMed ID: 31296342
[TBL] [Abstract][Full Text] [Related]
3. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
Descamps O; Tomassini JE; Lin J; Polis AB; Shah A; Brudi P; Hanson ME; Tershakovec AM
Atherosclerosis; 2015 Jun; 240(2):482-9. PubMed ID: 25913444
[TBL] [Abstract][Full Text] [Related]
4. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.
Krempf M; Simpson RJ; Ramey DR; Brudi P; Giezek H; Tomassini JE; Lee R; Farnier M
Lipids Health Dis; 2015 May; 14():45. PubMed ID: 25985907
[TBL] [Abstract][Full Text] [Related]
5. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
Miyoshi T; Nakamura K; Doi M; Ito H
Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
[TBL] [Abstract][Full Text] [Related]
6. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
7. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
8. Maximum Low-density Lipoprotein Cholesterol Lowering Capacity Achievable With Drug Combinations. When 50 Plus 20 Equals 60.
Masana L; Ibarretxe D; Plana N
Rev Esp Cardiol (Engl Ed); 2016 Mar; 69(3):342-3. PubMed ID: 26856792
[No Abstract] [Full Text] [Related]
9. [LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis].
Lahoz C; Mostaza JM; Pintó X; de la Cruz JJ; Banegas JR; Pedro-Botet J;
Clin Investig Arterioscler; 2015; 27(1):1-8. PubMed ID: 24882148
[TBL] [Abstract][Full Text] [Related]
10. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
11. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
[TBL] [Abstract][Full Text] [Related]
12. Getting there: statin plus ezetimibe for low-density lipoprotein cholesterol goals.
Hurley DL; Isley WL
Mayo Clin Proc; 2005 May; 80(5):585-6. PubMed ID: 15887424
[No Abstract] [Full Text] [Related]
13. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
[TBL] [Abstract][Full Text] [Related]
14. Lack of accurate evidence on non-statin medication in patients receiving highintensity statin therapy: Re-evaluation of recommendations is needed.
Demirci D; Ersan Demirci D
Anatol J Cardiol; 2018 Mar; 19(3):230. PubMed ID: 29521324
[No Abstract] [Full Text] [Related]
15. Ezetimibe: a novel option for lowering cholesterol.
Davidson MH
Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
[TBL] [Abstract][Full Text] [Related]
16. LDL-cholesterol: The lower the better.
Pedro-Botet J; Pintó X
Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():16-27. PubMed ID: 31813618
[TBL] [Abstract][Full Text] [Related]
17. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
18. [ANMCO Position paper: Clinical management of hypercholesterolemia in patients with acute coronary syndrome].
Colivicchi F; Gulizia MM; Arca M; Abrignani MG; Perna GP; Mureddu GF; Nardi F; Riccio C;
G Ital Cardiol (Rome); 2016 Jun; 17(6):456-61. PubMed ID: 27311088
[TBL] [Abstract][Full Text] [Related]
19. IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
Masana L; Pedro-Botet J; Civeira F
Atherosclerosis; 2015 May; 240(1):161-2. PubMed ID: 25795557
[No Abstract] [Full Text] [Related]
20. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
